UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In Re. ATP Life Science Ventures, L.P. §
§
§
Debtor(s) §

Case No. 25-12178

Lead Case No. 25-12177

☒ Jointly Administered

Monthly Operating Report

Chapter 11

Reporting Period Ended: 09/30/2026

Petition Date: 12/09/2025

Months Pending: 10

Industry Classification: 8 2 2 4

Reporting Method: Accrual Basis ○ Cash Basis ◉

Debtor's Full-Time Employees (current): 0

Debtor's Full-Time Employees (as of date of order for relief): 0

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- ☒ Statement of cash receipts and disbursements
- ☒ Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- ☒ Statement of operations (profit or loss statement)
- ☐ Accounts receivable aging
- ☐ Postpetition liabilities aging
- ☐ Statement of capital assets
- ☐ Schedule of payments to professionals
- ☐ Schedule of payments to insiders
- ☐ All bank statements and bank reconciliations for the reporting period
- ☐ Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Craig Martin
Signature of Responsible Party

Craig Martin
Printed Name of Responsible Party

11/09/2026
Date

1201 North Market Street, Suite 2100
Wilmington, Delaware 19801
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefo
1320.4(a)(2) applies.

25121772611090000000000001

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	$33,152,104	
b.	Total receipts (net of transfers between accounts)	$13,043	$100,436,071
c.	Total disbursements (net of transfers between accounts)	$8,324,843	$86,171,535
d.	Cash balance end of month (a+b-c)	$24,840,305	
e.	Disbursements made by third party for the benefit of the estate	$0	$0
f.	Total disbursements for quarterly fee calculation (c+e)	$8,324,843	$86,171,535

Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)		Current Month
a.	Accounts receivable (total net of allowance)	$0
b.	Accounts receivable over 90 days outstanding (net of allowance)	$0
c.	Inventory (Book ○ Market ○ Other ◉ (attach explanation))	$0
d	Total current assets	$3,540,670,498
e.	Total assets	$3,540,670,498
f.	Postpetition payables (excluding taxes)	$-1,816,177
g.	Postpetition payables past due (excluding taxes)	$0
h.	Postpetition taxes payable	$0
i.	Postpetition taxes past due	$0
j.	Total postpetition debt (f+h)	$-1,816,177
k.	Prepetition secured debt	$0
l.	Prepetition priority debt	$0
m.	Prepetition unsecured debt	$3,637,768
n.	Total liabilities (debt) (j+k+l+m)	$1,821,591
o.	Ending equity/net worth (e-n)	$3,538,848,907

Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	$0	$0
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	$0	$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	$0	$0

Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)		Current Month	Cumulative
a.	Gross income/sales (net of returns and allowances)	$369,340	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	$0	
c.	Gross profit (a-b)	$369,340	
d.	Selling expenses	$0	
e.	General and administrative expenses	$614,761	
f.	Other expenses	$0	
g.	Depreciation and/or amortization (not included in 4b)	$0	
h.	Interest	$0	
i.	Taxes (local, state, and federal)	$76	
j.	Reorganization items	$0	
k.	Profit (loss)	$-245,497	$-506,784

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

Part 5: Professional Fees and Expenses

				Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
a.	Debtor's professional fees & expenses (bankruptcy) *Aggregate Total*			$1,125,000	$1,125,000	$1,125,000	$1,125,000
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i	Eldridge Legal LLP	Local Counsel	$750,000	$750,000	$750,000	$750,000
	ii	Grant Thornton LLP (U.S.)	Financial Professional	$375,000	$375,000	$375,000	$375,000
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						
	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

	xxxvii						
	xxxvii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						
	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						
	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvi						
	lxxxvi						
	lxxxix						
	xc						
	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						

				Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
b.	Debtor's professional fees & expenses (nonbankruptcy) *Aggregate Total*						
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						
	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxvii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						
	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						
	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvi						
	lxxxvi						
	lxxxix						
	xc						
	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

	xcix						
	c						
c.	All professional fees and expenses (debtor & committees)			$1,125,000	$1,125,000	$1,125,000	$1,125,000

Part 6: Postpetition Taxes		Current Month	Cumulative
a.	Postpetition income taxes accrued (local, state, and federal)	$0	$0
b.	Postpetition income taxes paid (local, state, and federal)	$0	$0
c.	Postpetition employer payroll taxes accrued	$0	$0
d.	Postpetition employer payroll taxes paid	$0	$0
e.	Postpetition property taxes paid	$0	$0
f.	Postpetition other taxes accrued (local, state, and federal)	$0	$0
g.	Postpetition other taxes paid (local, state, and federal)	$0	$0

Part 7: Questionnaire - During this reporting period:

a.	Were any payments made on prepetition debt? (if yes, see Instructions)	Yes ○	No ◉
b.	Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)	Yes ○	No ◉
c.	Were any payments made to or on behalf of insiders?	Yes ◉	No ○
d.	Are you current on postpetition tax return filings?	Yes ◉	No ○
e.	Are you current on postpetition estimated tax payments?	Yes ◉	No ○
f.	Were all trust fund taxes remitted on a current basis?	Yes ○	No ◉
g.	Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)	Yes ○	No ◉
h.	Were all payments made to or on behalf of professionals approved by the court?	Yes ◉	No ○ N/A ○
i.	Do you have: Worker's compensation insurance?	Yes ○	No ◉
	If yes, are your premiums current?	Yes ○	No ○ N/A ◉ (if no, see Instructions)
	Casualty/property insurance?	Yes ◉	No ○
	If yes, are your premiums current?	Yes ◉	No ○ N/A ○ (if no, see Instructions)
	General liability insurance?	Yes ◉	No ○
	If yes, are your premiums current?	Yes ◉	No ○ N/A ○ (if no, see Instructions)
j.	Has a plan of reorganization been filed with the court?	Yes ○	No ◉
k.	Has a disclosure statement been filed with the court?	Yes ○	No ◉
l.	Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?	Yes ◉	No ○

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178

Part 8: Individual Chapter 11 Debtors (Only)

a.	Gross income (receipts) from salary and wages	$0
b.	Gross income (receipts) from self-employment	$0
c.	Gross income from all other sources	$0
d.	Total income in the reporting period (a+b+c)	$0
e.	Payroll deductions	$0
f.	Self-employment related expenses	$0
g.	Living expenses	$0
h.	All other expenses	$0
i.	Total expenses in the reporting period (e+f+g+h)	$0
j.	Difference between total income and total expenses (d-i)	$0
k.	List the total amount of all postpetition debts that are past due	$0
l.	Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?	Yes ○ No ◉
m.	If yes, have you made all Domestic Support Obligation payments?	Yes ○ No ○ N/A ◉

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.


/s/ Barry Lynch
Signature of Responsible Party

Barry Lynch
Printed Name of Responsible Party


Officeholder
Title

11/09/2026
Date


Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178




PageOnePartOne



PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo


Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178




Bankruptcy1to50



Bankruptcy51to100




NonBankruptcy1to50




NonBankruptcy51to100

Debtor's Name ATP Life Science Ventures, L.P. Case No. 25-12178



PageThree



PageFour

In re: ATP Life Science Ventures, L.P.
Case No. 25-12178 (LSS)
Statement of Cash Receipts and Disbursements
For the month ended September 30, 2026
($)

	ATP Life Science Ventures, L.P.
Beginning Bank Cash Balance	$ 33,152,104
Receipts:	
Non-Intercompany Receipts	13,043
Intercompany Receipts - Debtor	-
Intercompany Receipts - Non-Debtor	-
Disbursements:	
Non-Intercompany Disbursements	(8,324,843)
Intercompany Disbursements - Debtor	-
Intercompany Disbursements - Non-Debtor	-
Ending Bank Cash Balance	$ 24,840,305

In re: ATP Life Science Ventures, L.P.
Case No. 25-12178 (LSS)
Balance Sheet
As of September 30, 2026
($)

	ATP Life Science Ventures, L.P.
Assets	
Cash and cash equivalents	$ 24,840,305
Intercompany receivables	42,892,401
Other receivables	357,208,001
Prepaid expenses and other assets	23,458,919
Investments, at cost	1,215,901,044
Unrealized gain / (loss) on investments	1,876,369,829
Total assets	$ 3,540,670,498
Liabilities and Partners' Capital	
Liabilities	
Intercompany Payables	$ 1,821,591
Total liabilities	$ 1,821,591
Partners' capital	
Capital contributions	2,441,660,436
Capital and carry distributions	(2,284,851,803)
Opening balance equity	2,765,901,440
Retained earnings and accumulated income / (loss)	616,138,834
Total partners' capital	$ 3,538,848,907
Total liabilities and partners' capital	$ 3,540,670,498

In re: ATP Life Science Ventures, L.P.
Case No. 25-12178 (LSS)
Statement of Operations
For the month ended September 30, 2026
($)

	ATP Life Science Ventures, L.P.
Revenue, net	$ 369,340
Gross profit (loss)	369,340
Selling, general and administrative expenses	614,761
Other operating taxes	76
Income (loss) from operations	(245,497)
Income (loss) before income taxes	(245,497)
Net income (loss)	$ (245,497)

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
APPLE TREE LIFE SCIENCES, INC., *et al*.,[1]	Case No. 25-12177 (LSS)
Debtors.	(Jointly Administered)

GLOBAL NOTES AND STATEMENTS
OF LIMITATIONS AND DISCLAIMERS REGARDING THE
MONTHLY OPERATING REPORT OF ATP LIFE SCIENCE VENTURES, L.P.
FOR THE PERIOD OF SEPTEMBER 1, 2026, THROUGH SEPTEMBER 30, 2026

On December 9 and 15, 2025, and January 1 and 15, 2026 (the "Petition Dates"), the above-captioned debtors and debtors in possession (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). The Debtors' chapter 11 cases are being jointly administered for procedural purposes only pursuant to rule 1015(b) of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules") and rule 1015-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the "Local Rules") under the caption *Apple Tree Life Sciences, Inc., et al.*, Case No. 25-12177 (LSS), pursuant to the *Order Directing Joint Administration of the Debtors' Chapter 11 Cases* [D.I. 69] and the *Orders (I) Directing Joint Administration of Additional Chapter 11 Cases and (II) Extending Certain Relief Granted to the Original Debtors* [D.I. 178 & 200]. On January 20, 2026, the United States Trustee for the District of Delaware (the "U.S. Trustee") appointed the Official Committee of Unsecured Creditors (the "Creditors' Committee") [D.I. 194].

The following notes, statements, and limitations should be referred to, and referenced in connection with, any review of the monthly operating report of ATP Life Science Ventures, L.P. (the "Fund") for the period of September 1, 2026, through September 30, 2026 (the "MOR").

The MOR was prepared by the Fund's advisors, Alvarez & Marsal ("A&M"), based on information derived from the Fund's books and records. The Fund and A&M have made reasonable efforts to ensure the accuracy and completeness of the financial information presented in the MOR.

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The service address for ATP Life Science Ventures, L.P. is c/o Alvarez & Marsal Cayman Islands Limited, Attn: Kim Dennison, 2nd Floor, Flagship Building, 142 Seafarers Way, P.O. Box 2507, George Town, Grand Cayman, Cayman Islands, KY1-1104. The service address for each of the remaining Debtors is 230 Park Avenue, Suite 2800, New York, NY 10169.

The Fund and its advisors do not guarantee or warrant the accuracy or completeness of the data that is provided herein and shall not be liable for any loss or injury arising out of or caused in whole or in part by the acts, errors, or omissions, whether negligent or otherwise, in procuring, compiling, collecting, interpreting, reporting, communicating, or delivering the information contained herein. In no event shall the Fund and/or its advisors be liable to any third party for any direct, indirect, incidental, consequential, and/or special damages (including, but not limited to, damages arising from the disallowance of a potential claim against the Fund or damages to business reputation, lost business, or lost profits), whether foreseeable or not and however caused, even if the Fund and/or its advisors are advised of the possibility of such damages.

These global notes regarding the MOR (the "Global Notes") pertain to, are incorporated by reference in, and comprise an integral part of, the MOR. The Global Notes are in addition to the specific disclosures set forth below with respect to the MOR (the "Specific Disclosures" and, together with the Global Notes, the "Notes"). The Notes are filed solely on behalf of, and relate solely to the MOR of, the Fund. The Notes are not filed on behalf of any other Debtor and do not purport to supplement, describe, or explain the monthly operating report of any other Debtor, each of which is filed separately.

Global Notes Regarding the Fund's MOR

1. **Basis of Presentation**. The Fund is filing the MOR solely for purposes of complying with the monthly operating reporting requirements applicable in the Fund's chapter 11 case. The MOR is in a format acceptable to the U.S. Trustee. The MOR should not be relied upon by any persons for information relating to past, current, or future financial conditions, events, or performance of the Fund or its affiliates.

   In preparing the MOR, A&M relied on historical financial data derived from the Fund's books and records that was available at the time of preparation. The historical data may be incomplete or inaccurate. The books and records have historically been kept on an accrual basis. The MOR uses a modified cash basis of presentation: Part 1 reports actual cash receipts and disbursements, while the supporting balance sheet and statement of operations retain accrual and other noncash amounts reflected in the books and records, including intercompany balances, interest and other receivables, prepaid expenses, and investment valuation adjustments. Accordingly, the Fund's supporting financial statements do not reflect solely cash transactions and have not been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Subsequent information or discovery may result in material changes to the MOR, and inaccuracies, errors, or omissions may exist. Notwithstanding any such discovery, new information, or errors or omissions, the Fund does not undertake any obligation or commitment to update the MOR.

   Joint Officeholders' Review and Reservation of Rights. The Joint Officeholders of the Fund (the "JOHs") are investigating the trial balance and balance sheet position of the Fund. Several items remain unverified, and the amounts and classifications presented in the MOR and supporting schedules are subject to material change. Neither the filing of the MOR nor the inclusion of the Fund's trial

balance, balance sheet, or other supporting information constitutes an admission, acceptance, or confirmation by the JOHs that any balance, transaction, classification, or prior accounting treatment is correct.

Intercompany Balances. Intercompany balances remain subject to ongoing reconciliation and potential disputes, including the treatment and netting of intercompany receivables against intercompany payables. Such reconciliation may result in adjustments or reclassifications to amounts reported in prior periods, including opening balances.

The MOR has not been prepared in accordance with U.S. GAAP and does not include all of the information and footnotes required by U.S. GAAP. Further, the information contained in the MOR may not reflect in all circumstances presentation requirements for International Financial Reporting Standards, or any other accounting principles generally accepted in specific countries. Therefore, there can be no assurance that the financial information presented herein is complete, and readers are strongly cautioned not to place undue reliance on the MOR.

Furthermore, the monthly financial information contained herein has not been subjected to the same level of accounting review and testing that the Fund applies in the preparation of its annual financial information in accordance with U.S. GAAP. Accordingly, upon the application of such procedures, the Fund believes that the financial information may be subject to change, and these changes could be material.

In future periods, any changes to prior period balances will be reflected in the current month's MOR.

The results of operations contained herein are not necessarily indicative of results that may be expected from any other period or for the full year and may not necessarily reflect the results of operations and financial position of the Fund in the future.

These unaudited financial statements are prepared to support the information required in the MOR and should not be used for any other purpose.

2. **Reporting Period**. Unless otherwise noted herein, the MOR generally reflects the Fund's books and records and financial activity occurring during the applicable reporting period. Except as otherwise noted, no adjustments have been made for activity occurring after the close of the reporting period.

3. **Accuracy**. The financial information disclosed herein was not prepared in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or transferring the claims against or equity interests in the Fund should evaluate this financial information in light of the purposes for which it was prepared. The Fund is not liable for and undertakes no responsibility to indicate variations from

securities laws or for any evaluations of the Fund based on this financial information or any other information.

4. **Payment of Prepetition Claims Pursuant to Payment Orders**. Following the Petition Dates, the Bankruptcy Court entered various orders authorizing the Debtors to, among other things, pay certain prepetition claims, including without limitation: insurance obligations; employee wages, salaries, and related items (including, but not limited to, employee benefit programs and contractor wage obligations); and other obligations (collectively, the "Payment Orders"). To the extent any payments were made by the Fund on account of such claims or obligations following the commencement of its chapter 11 case pursuant to the authority granted by the Bankruptcy Court under the Payment Orders, such payments have been included in the MOR unless otherwise noted.

5. **Insiders**. For purposes of the MOR, the Fund has defined "insiders" as is provided in section 101(31) of the Bankruptcy Code during the relevant time period. The Fund does not concede or take any position with respect to (a) such person's influence over the control of the Fund; (b) the management responsibilities or functions of such individual; (c) the decision-making or corporate authority of such individual; or (d) whether such individual could successfully argue that he or she is not an "insider" under applicable law, including, without limitation, the federal securities laws or with respect to any theories of liability or any other purpose. Further, the inclusion of a party as an "insider" solely for purposes of the MOR is not an acknowledgment, admission, or concession that such party is an "insider" under applicable bankruptcy law.

6. **Reservation of Rights**. The Fund reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing contained in the MOR shall constitute a waiver of any of the Fund's rights or an admission with respect to its chapter 11 case. Any specific reservation of rights contained elsewhere in these Notes does not limit in any respect the general reservation of rights contained in this paragraph, including, but not limited to, the following:

   a. Nothing contained in the MOR is intended or should be construed as an admission or stipulation of the validity or allowance of any claim against the Fund, any assertion made therein or herein, or a waiver of the right to dispute the allowance of or any distributions in connection with any claim or assert any cause of action or defense against any party.

7. **Notes Control**. Disclosure of information in any part of the MOR, even if incorrectly placed, shall be deemed to be disclosed in the correct part of the MOR. In the event that the MOR differs from any of these Notes, these Notes shall control.

8. **Specific Disclosures**

   a. **Notes to Part 1: Cash Receipts and Disbursements:** This section is prepared on a cash basis. Further details with respect to the Debtors' cash management system and bank accounts are also provided in the *Final Order (I) Authorizing the Debtors to (A) Continue to Operate Their Cash Management System and (B) Honor Certain Pre-Petition Obligations Related Thereto, and (II) Granting Related Relief* [D.I.

189] and the *Order (I) Directing Joint Administration of Additional Chapter 11 Cases and (II) Extending Certain Relief Granted to the Original Debtors* [D.I. 200].

b. **Notes to Part 2: Asset and Liability Status:** The Fund reports this section on the modified cash basis described above. The amounts identified in Part 2 of the MOR are derived from the Fund's unaudited and estimated balance sheet as of close of business on the last day of the reporting period. Please refer to the notes above for information about presentation and limitations related to the MOR.

   i. **Current Asset Presentation.** Consistent with prior accounting practices, the Fund does not distinguish between current and noncurrent assets; as a result, all assets of the Fund are presented as current in Part 2 of the MOR. This does not represent a determination that all investments or other assets will be sold or otherwise realized within one year and remains subject to review and revision.

   ii. **Intercompany Credit and Debit Balances.** Certain intercompany receivable accounts carry net credit balances, and certain intercompany payable accounts carry net debit balances, within the Fund's books and records. Consistent with the underlying general ledger, these balances are presented in the MOR as negative assets and negative liabilities, respectively. As a result, the MOR may reflect negative current assets, total assets, and/or postpetition payables for the Fund on an unconsolidated basis. These intercompany balances eliminate in consolidation.

   iii. **Trade Receivables.** The Fund has no trade accounts receivable and therefore reports zero trade accounts receivable in Part 2 of the MOR. Intercompany and other receivables are included separately in the supporting balance sheet and remain included in total assets.

c. **Notes to Part 4: Income Statement (Statement of Operations):** The Fund reports this section on the modified cash basis described above. The amounts identified in Part 4 of the MOR are derived from the Fund's unaudited statement of operations as of close of business on the last day of the reporting period.

d. **Notes to Part 5: Professional Fees and Expenses:**

   i. The Debtors will pay the professional fees and expenses of their retained bankruptcy professionals in accordance with the *Order (I) Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals and (II) Granting Related Relief* [D.I. 181] (the "Interim Compensation Order"). The Debtors will pay the professional fees and expenses of their other professionals (non-bankruptcy) in accordance with the *Order (I) Authorizing Debtors to Employ Professionals Utilized in the Ordinary Course of Business, (II) Waiving Certain Information*

Requirements of Local Rule 2016-1, and (III) Granting Related Relief [D.I. 192]. The Debtors will pay the professional fees and expenses incurred by the Creditors' Committee and any other official committee appointed by the U.S. Trustee in accordance with the Interim Compensation Order.

ii. On June 23, 2026, the Bankruptcy Court entered the *Order Granting the Application of the Debtors to Retain and Employ Grant Thornton LLP as Independent Auditor* [D.I. 813] (the "Grant Thornton Retention Order"), authorizing the Debtors to retain and employ Grant Thornton LLP ("Grant Thornton") as independent auditor, effective as of May 20, 2026, pursuant to sections 327(a) and 328(a) of the Bankruptcy Code. The Grant Thornton Retention Order provides that Grant Thornton shall apply for compensation in accordance with the procedures set forth in sections 330 and 331 of the Bankruptcy Code, the applicable Bankruptcy Rules, the Local Rules, and such other procedures as may be fixed by order of the Bankruptcy Court. On September 30, 2026, the Fund transferred to Grant Thornton $375,000, representing the full amount of the fixed fee under Grant Thornton's engagement. Following discussions with the U.S. Trustee, Grant Thornton has agreed to escrow the entirety of the payment will file a fee application in accordance with the Grant Thornton Retention Order. Grant Thornton will not draw upon the escrowed funds until entry of an appropriate order of the Bankruptcy Court.

iii. **Eldridge Legal Retainer.** The Fund's September cash disbursements and professional payments include a $750,000 retainer paid to Eldridge Legal LLP. This payment has not been recognized as an expense in the Fund's September statement of operations.

e. **Notes to Part 7: Questionnaire:**

i. Question (c) – The Fund has answered "Yes" to Question (c) on the MOR form where compensation or expense reimbursement payments to officers, directors, or other insiders were made in the ordinary course of business.

ii. Question (f) – The Fund is not required to remit trust fund taxes and has, therefore, responded "No" to Question (f) on the MOR form.

iii. Question (g) – In accordance with the *Interim Order to (I) Make and Accept Secured Loans to Portfolio Companies, (II) Authorize to the Extent Outside the Ordinary Course of Business Payment of Management Company Expenses and (III) Grant Related Relief* [D.I. 102], the *Final Order to (I) Make and Accept Secured Loans to Portfolio Companies, (II) Authorize to the Extent Outside the Ordinary Course of Business Payment of Management Company Expenses and*

(III) Grant Related Relief [D.I. 206], and the *Interim Order (I) Authorizing Use of Funds to (A) Fund Portfolio Companies, (B) Pay Management Company Expenses and (C) Pay Chapter 11 Expenses, and (II) Granting Related Relief for the Limited Purpose of Obtaining Certain Interim Funding* [D.I. 561] (the "Funding Orders"), the Fund provided secured loans to certain Portfolio Debtors (as defined in the Funding Orders) pursuant to sections 363(b) and 364 of the Bankruptcy Code. Accordingly, the Fund responded "Yes" to Question (g) on the MOR form.